Compare Pfizer Inc (PFE) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while Consumer Staples Select Sector SPDR Fund trades at $83.05 (market cap $13.44B). The key difference: Pfizer Inc is far larger — about 11.9× Consumer Staples Select Sector SPDR Fund's market cap, and Pfizer Inc pays a 6.14% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| PFE | XLP | |
|---|---|---|
Market Cap | $159.59B | $13.44B |
Volume | 30,937,010 | 9,437,177 |
Sector | Health | — |
52-Week High | $29.02 | $90.00 |
52-Week Low | $23.67 | $75.61 |
Typical Hold Time | 158 Days | 72 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
XLP trades at $81.70, down 0.09% with a bearish technical outlook as moving averages signal selling pressure. The ETF shows strong analyst support with a 100% buy rating from 2 analysts. Recent news highlights XLP's 6.6% YTD gain outperforming discretionary peers, though it faces headwinds from rising interest rates pressuring dividend stocks.
XLP offers defensive exposure to consumer staples with a low 0.08% expense ratio and upcoming dividend. Key risks include persistent inflation and interest rate sensitivity, but the fund's quality holdings provide stability during market volatility. The technical setup suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
